Reteplase
- Atc Codes:B01AD07
- CAS Codes:133652-38-7
- PHARMGKB ID:133652-38-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Rapilysin; Belgium: Rapilysin; Bulgaria: Rapilysin; Czech Republic: Rapilysin; Denmark: Rapilysin; Estonia: Rapilysin; Finland: Rapilysin; France: Rapilysin; Germany: Rapilysin; Greece: Rapilysin; Hungary: Rapilysin; Ireland: Rapilysin; Italy: Rapilysin; Latvia: Rapilysin; Lithuania: Rapilysin; Luxembourg: Rapilysin; Malta: Rapilysin; Netherlands: Rapilysin; Poland: Rapilysin; Portugal: Rapilysin; Romania: Rapilysin; Slovakia: Rapilysin; Slovenia: Rapilysin; Spain: Rapilysin; Sweden: Rapilysin; UK: Rapilysin.
North America
Canada: Retavase; USA: Retavase.
Drug combinations
Chemistry
Reteplase: C~1736~H~2653~N~499~O~522~S~22~. Mw: 39,571.14. (1) 173-527-Plasminogen activator (human tissue-type), 173-L-serine-174-L-tyrosine-175-L-glutamine-; (2) 173-L-Serine-174-L-tyrosine-175-L-glutamine-173-527-plasminogen activator (mutant of human tissue-type). CAS-133652-38-7 (1997).
Pharmacologic Category
Thrombolytic Agents. Enzymes. (ATC-Code: B01AD07).
Mechanism of action
A nonglycosylated form of tissue plasminogen activator (TPA) produced by recombinant DNA technology using E. coli. Initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin.
Therapeutic use
Management of ST-elevation myocardial infarction. Improvement of ventricular function. Reduction of incidence of CHF and reduction of mortality following acute myocardial infarction.
Pregnancy and lactiation implications
Use with caution in pregnancy (increased risk of bleeding). Excretion in breast milk unknown (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to reteplase or any component of the formulation. Active internal bleeding. History of cerebrovascular accident. Recent intracranial or intraspinal surgery or trauma. Intracranial neoplasm, arteriovenous malformations, or aneurysm. Known bleeding diathesis. Severe uncontrolled hypertension.
Warnings and precautions
Rare anaphylactic reactions can occur. Coronary thrombolysis may result in reperfusion arrhythmias. Bleeding might occur. Cholesterol embolism rarely reported. Use with caution in patients receiving oral anticoagulants (increased risk of bleeding). Concurrent heparin anticoagulation may contribute to bleeding. Intramuscular injections should be avoided. Venipunctures should be performed only when necessary.